Brief: Curis Announces FDA Partial Clinical Hold For Takeaim Lymphoma Study Of Emavusertib (CA-4948)
11/04/2022 15:50
Curis Inc CRIS.O :
* CURIS ANNOUNCES FDA PARTIAL CLINICAL HOLD FOR TAKEAIM
LYMPHOMA
STUDY OF EMAVUSERTIB (CA-4948)
* CURIS INC - THIS WEEK'S NOTIFICATION EXTENDS PARTIAL HOLD
ACROSS
BOTH STUDIES
* CURIS INC - WHILE PARTIAL HOLD ON TAKEAIM LYMPHOMA STUDY
IS IN
PLACE, NO NEW PATIENTS WILL BE ENROLLED IN THAT STUDY
* CURIS -CURRENT PARTICIPANTS BENEFITING FROM TREATMENT MAY
CONTINUE TO BE TREATED WITH EMAVUSERTIB AT DOSES OF 300MG OR
LOWER AFTER BEING RECONSENTED
Source text for Eikon: ID:nPn9WbyxPa
Further company coverage: CRIS.O
Recent news on Curis
See all newsCuris Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Curis Announces Pricing Of $5.6 Million Public Offering
Curis Inc expected to post a loss of $7.84 a share - Earnings Preview
Curis Inc expected to post a loss of $7.47 a share - Earnings Preview
Brief: Curis Doses First Five Patients In Takeaim Cll Study